Skip to content

Effects of dienogest and oral contraceptive pills on endometriosis symptoms after laparoscopic surgery

Comparative study on the effects of continuous administration of dienogest and continuous oral contraceptive pills on the recurrence of endometriosis symptoms after laparoscopic surgery

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20120201008897N7
Enrollment
80
Registered
2019-05-02
Start date
2019-06-15
Completion date
Unknown
Last updated
2019-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

laparoscopy of endometriosis. Endometriosis, unspecified

Interventions

Intervention 1: Intervention group 1: group receiving dinogest 2mg/day continuously after surgery for 6 months. Intervention 2: Intervention group 2 : group receiving oral contraceptive (low dose mono

Sponsors

Esfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: Patients with diagnosis endometriosis via laparoscopy Premenopausal patients Patients who have symptoms of endometriosis before surgery (eg: dysmenorrhea, dyspareunia, chronic pelvic pain) Patients who have been referred to Isfahan's Alzhra and Shahid Beheshty hospitals Patients who do not have any decision for pregnancy during this study Patients with 20-40 years of age

Exclusion criteria

Exclusion criteria: Any hormonal therapy 3 months before surgery Having contraindications for using oral contraceptives Changing in the address so there is no access to the patient and her information History of surgery for treatment of endometriosis History of sexual dysfunction in patient or the partner Clients who undergo hysterectomy or ouophurectomy during surgery History of malignancy or heart disease

Design outcomes

Primary

MeasureTime frame
Recurrence of endometriosis. Timepoint: 6 months. Method of measurement: visual analog scale, WHO quality of life brief (WHOQOL-BREF) , Female Sexual Function Index (FSFI).;Pain. Timepoint: 6 months. Method of measurement: visual analog scale, WHO quality of life brief ( WHOQOL-BREF), Female sexual function index (FSFI).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactReihaneh Valian Broujeni

Esfahan University of Medical Sciences

s_rouholamin@med.mui.ac.ir+98 31 3236 7001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026